Diagnostic Accuracy of Tumor Markers CYFRA21-1 and CA125 in the Differential Diagnosis of Ascites
Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved..
BACKGROUND: The usefulness of tumor markers in the differential diagnosis of cancer in patients with ascites remains a matter of controversy. Few studies have reported the measurement of cancer antigen 125 (CA125) and cytokeratin 19 soluble fragments (CYFRA21-1) in ascitic fluid. The aim of the present study was to evaluate the diagnostic accuracy of these tumor markers in the detection of malignant ascites.
MATERIALS AND METHODS: We analyzed CA125 and CYFRA21-1 from 143 consecutive undiagnosed patients with ascitis.
RESULTS: Use of CA125 gave a sensitivity of 39.7% and a specificity of 98.8%, and CYFRA21-1 a sensitivity of 50.0% and a specificity of 97.6% in differential diagnosis of malignant ascites. For combined use of CA125 plus CYFRA21-1, sensitivity was 65.5% and specificity 96.5%. In patients with negative cytology, these two tumor markers had a sensitivity of 50% and a specificity of 96.5%.
CONCLUSION: The determination of tumor markers in ascitic fluid could be useful for the diagnostic assessment of patients with ascites.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Anticancer research - 35(2015), 10 vom: 01. Okt., Seite 5655-60 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Trapé, Jaume [VerfasserIn] |
|---|
| Themen: |
Antigen CYFRA21.1 |
|---|
| Anmerkungen: |
Date Completed 05.01.2016 Date Revised 11.03.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM253121639 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM253121639 | ||
| 003 | DE-627 | ||
| 005 | 20231224165543.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0843.xml |
| 035 | |a (DE-627)NLM253121639 | ||
| 035 | |a (NLM)26408739 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Trapé, Jaume |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnostic Accuracy of Tumor Markers CYFRA21-1 and CA125 in the Differential Diagnosis of Ascites |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2016 | ||
| 500 | |a Date Revised 11.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. | ||
| 520 | |a BACKGROUND: The usefulness of tumor markers in the differential diagnosis of cancer in patients with ascites remains a matter of controversy. Few studies have reported the measurement of cancer antigen 125 (CA125) and cytokeratin 19 soluble fragments (CYFRA21-1) in ascitic fluid. The aim of the present study was to evaluate the diagnostic accuracy of these tumor markers in the detection of malignant ascites | ||
| 520 | |a MATERIALS AND METHODS: We analyzed CA125 and CYFRA21-1 from 143 consecutive undiagnosed patients with ascitis | ||
| 520 | |a RESULTS: Use of CA125 gave a sensitivity of 39.7% and a specificity of 98.8%, and CYFRA21-1 a sensitivity of 50.0% and a specificity of 97.6% in differential diagnosis of malignant ascites. For combined use of CA125 plus CYFRA21-1, sensitivity was 65.5% and specificity 96.5%. In patients with negative cytology, these two tumor markers had a sensitivity of 50% and a specificity of 96.5% | ||
| 520 | |a CONCLUSION: The determination of tumor markers in ascitic fluid could be useful for the diagnostic assessment of patients with ascites | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Ascitic fluid | |
| 650 | 4 | |a CA125 | |
| 650 | 4 | |a CYFRA 21-1 | |
| 650 | 4 | |a differential diagnosis | |
| 650 | 4 | |a malignant effusion | |
| 650 | 7 | |a Antigens, Neoplasm |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a CA-125 Antigen |2 NLM | |
| 650 | 7 | |a Carcinoembryonic Antigen |2 NLM | |
| 650 | 7 | |a Keratin-19 |2 NLM | |
| 650 | 7 | |a antigen CYFRA21.1 |2 NLM | |
| 700 | 1 | |a Gurt, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Franquesa, Josefina |e verfasserin |4 aut | |
| 700 | 1 | |a Montesinos, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Arnau, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Sala, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Sant, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Casado, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Ordeig, Josep Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Bergos, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Vida, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Sort, Pau |e verfasserin |4 aut | |
| 700 | 1 | |a Isava, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a González, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Molina, Rafael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d 1987 |g 35(2015), 10 vom: 01. Okt., Seite 5655-60 |w (DE-627)NLM012601454 |x 1791-7530 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2015 |g number:10 |g day:01 |g month:10 |g pages:5655-60 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2015 |e 10 |b 01 |c 10 |h 5655-60 | ||